The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1434
Antiviral Drugs for Influenza 2013-2014
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Antiviral drugs can be used for treatment of influenza and as an adjunct to influenza vaccination1 for prophylaxis. Frequently updated information on antiviral resistance is available at www.cdc.gov.

NEURAMINIDASE INHIBITORS — Oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), which is inhaled, can be used for either chemoprophylaxis or treatment. When used for chemoprophylaxis after exposure to susceptible strains of seasonal influenza A or B viruses, they have generally been about 70-90% effective.2

In mild illness, treatment with a neuraminidase inhibitor started within 48 hours after the onset of illness in patients infected with a susceptible strain of influenza virus can decrease the duration of fever and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Antiviral Drugs for Influenza 2013-2014
Article code: 1434b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian